Vertex Pharmaceuticals Inc (VRTX)

186.94
-3.17(-1.67%)
Pre Market
187.99
+1.05(+0.56%)
- Real-time Data
  • Volume:
    3,869,976
  • Bid/Ask:
    186.70/188.00
  • Day's Range:
    186.26 - 192.62

VRTX Overview

Prev. Close
190.11
Day's Range
186.26-192.62
Revenue
7.13B
Open
189.5
52 wk Range
176.36-242.9
EPS
8.34
Volume
3,869,976
Market Cap
47.53B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,598,175
P/E Ratio
22.41
Beta
0.6
1-Year Change
-17.92%
Shares Outstanding
254,251,938
Next Earnings Date
Feb 02, 2022
What is your sentiment on Vertex Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Vertex Pharmaceuticals Inc Company Profile

Employees
3400

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellNeutralNeutralSell
Technical IndicatorsSellStrong SellStrong SellNeutralStrong Sell
SummarySellStrong SellSellNeutralStrong Sell
  • it's so underpriced
    0
    • was there a stock split last 12 months?
      0
      • Nope?
        0
      • No
        0
    • was there a stock split last 12 months?
      0
      • this is almost half price from peak now
        0
        • this is almost half price from peak now
          0
          • Can’t wait for monday
            0
            • Great results 🥳
              0
              • another drop ...
                0
                • Will go up next week
                  1
                • Not
                  0
              • premarket +2, then market opens and it's slump... what happened ? does somebody know ?
                0
                • why has the stock crashed so much last 4 months?
                  0
                  • Inside this company is a disfunctional mess.
                    0
                • undervalued buy buy
                  0
                  • Order.market reiterated its outperform rating on Vertex $VRTX. Go go go $VRTX
                    1
                • stock moved 50 cents upon good ER,
                  1
                  • Good earnings & better outlook
                    1
                    • hi
                      0
                      • Hi
                        0
                    • i made a very conservative dcf and 208. this stock is undervalued
                      0
                      • Just VRTX
                        0
                        • today we will recieve a massive punch. hope it resist 175
                          10
                          • I have previously said my opinion on this company. options for the next week are selling at 195-20 for a total of over 0.5 billion. I don't think it's a coincidence. high probability of leakage of inside information long before the decision. Also suggestive of price manipulation. in short, the SEC needs to take a close look at all this
                            2
                            • Shares of Vertex Pharmaceuticals tumbled 13% in after-hour trading after the company announced it would end its development of VX-864, a liver-disease drug. Vertex said in a press release that “the magnitude of treatment effect observed in this study is unlikely to translate into substantial clinical benefit.”
                              0
                              • Just need 230 but waiting for 7 months already..
                                0
                                • good news !
                                  0
                                  • OK so how do you explain Moderna price comparing with aztrazeneca or Pfizer?
                                    0
                                  • Guy's !! ✌ Michal and André, i'm from Denmark 🇩🇰 and Michal you were talking about Novo Nordisk, so i have had them stocks, guys totally flat line, i had enough and sold them with profit, but here's the thing, you're kinda saying the same if you would stop being more wise than the other, so here is What i Do Not Understand ! Why oh why a these pharmaceutical companies that are pushing vaccines, not sky rocket 🤔🤔🤔 it makes no freaking sense, they make a billion vaccines, but there stock do not go up, did you know way before the pandemic started, about 16 companies each bought for 100 million in pharmaceutical stocks, makes you wonder doesn't it..?? 🤔🤔🤔 So is the break out do a long time ago, and now we are just standing still, until there next move for a higher high...
                                    0
                                  • Are we first gonna see some movement in Q3/Q4 ??? They must have a plan to make even more money with all the debt they have, and with Bitcoin dominating the most of the world right now, no to mention that there's talk about yet another Market Crash coming soon, and it will hit hard this time, so if i look forward, i would say that metals/gold/silver and Cryptocurrency is the only way not to suffer the damage to come, i don't know, i am just saying, don't listen to me...
                                    0
                                • Does anybody know what the ********is going on here?
                                  0
                                  • No but i’m waiting for EMA valutation
                                    0
                                • Why is so flat?
                                  0
                                  • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
                                    4
                                    • hopefully reach 230 @Earning
                                      1
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.